نتائج البحث

تحتوي على الكلمات

فقط من النوع

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease قائمة الدراسات السريرية المسجلة على الادوية

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care(FIGARO -DKD) قائمة الدراسات السريرية المسجلة على الادوية

EMEA CTEPH Registry: An international prospective registry investigating the epidemiology, diagnosis and treatment of CTEPH patients in EMEA countries. قائمة الدراسات السريرية المسجلة على الادوية

وفد من منظمة الصحة العالمية يزور "الغذاء والدواء" خبر

EXPERT, EXPosurE Registry RiociguaT in patients with pulmonary hypertension قائمة الدراسات السريرية المسجلة على الادوية

"Tranexamic acid for the treatment of significant traumatic brain injury:an international randomised, double blind placebo controlled trial" قائمة الدراسات السريرية المسجلة على الادوية

"“MERS-CoV Infection Treated with a Combination ofLopinavir/Ritonavir and Interferon Beta 1B: A Placebo-Controlled, Double-BlindRandomized Trial (MIRACLE Trial)”" قائمة الدراسات السريرية المسجلة على الادوية

A three-arm, randomized, open-label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenupausal women with estrogen receptor postive, locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole. قائمة الدراسات السريرية المسجلة على الادوية

A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-18 months of age), a 1+1 primary and booster (6 and 15-18 months of age), or as a single dose at 15-18 months of age قائمة الدراسات السريرية المسجلة على الادوية

"A RANDOMIZED, PARTIALLY-BLIND, PLACEBO-CONTROLLED, PILOT, DOSE-RANGING STUDY TO ASSESS THE EFFECT OF GWP42003 ON LIVER FAT LEVELS IN SUBJECT WITH FATTY LIVER DISEASE" قائمة الدراسات السريرية المسجلة على الادوية